New York, May 21, 2026, 10:04 (EDT)
- Pomdoctor’s ADSs on Nasdaq traded at $0.1153 in early U.S. hours, off $0.0094 from the last close.
- The stock changed hands in regular Nasdaq hours. Nasdaq’s 2026 calendar puts the next U.S. market holiday on Memorial Day, May 25.
- The company is still in a Nasdaq minimum-bid cure period that runs until July 28.
Pomdoctor Limited shares slipped in early Nasdaq trade Thursday. The Chinese digital-health microcap is still working to regain compliance with the $1 minimum bid level on the exchange.
The American depositary shares, or ADSs, were last at $0.1153, down $0.0094 from the previous close. Volume showed 172,520 shares traded. Market data put the session low at $0.1153.
Pomdoctor got a warning from Nasdaq back in February — its ADSs fell under the $1 minimum bid for 33 business days in a row, the company said. Nasdaq set a July 28 deadline for Pomdoctor to fix it. They need at least $1 on the closing bid, the price buyers are willing to pay, for 10 business days straight to get back in line.
Pomdoctor is under pressure after posting higher revenue but a steeper loss for 2025 last week. The Guangzhou-based company said net revenue was up 16.7% to RMB399.9 million. Net loss ballooned to RMB130.9 million, compared with RMB37.4 million a year earlier. Gross margin dropped to 13.1% from 13.9%.
Pomdoctor chairman and CEO Zhenyang Shi described 2025 as a year for “solid revenue expansion.” Shi said the company is still confident about China’s digital healthcare market. He mentioned stepped-up spending on AI and healthcare R&D. PR Newswire
Pomdoctor’s Internet hospital unit led the gains this period. The segment’s revenue jumped 69.3% to RMB150.7 million, mainly on stronger online pharmacy sales. But pharmaceutical supply-chain revenue slipped 1.7% to RMB249.2 million. The company also said it closed two retail stores, blaming heavy competition in the retail pharmacy market.
Pomdoctor is up against stiff competition in China’s online health space. JD Health’s operation covers both retail pharmacy and healthcare services, and Alibaba calls Alibaba Health a flagship healthcare platform, keeping it inside its main group. Both JD Health and Alibaba Health are bigger names for investors sizing up Chinese online pharmacy and digital-care plays.
Stocks got off to a weak start. The Nasdaq Composite dropped 0.48% at the open as oil prices rose on Middle East worries, Reuters said. Pomdoctor’s shares sold off more than the market did early.
But risk goes beyond just today’s price. Pomdoctor reported net cash used in operating activities of RMB148.5 million for 2025 and ended the year with RMB9.6 million in cash and cash equivalents. If the ADSs don’t get back above $1 and stay there by the July deadline, it’s uncertain whether Nasdaq will grant more time or if the company will need to act to keep its listing.
Pomdoctor debuted on the Nasdaq Global Market in October at $4 per ADS and brought in about $23 million in gross proceeds, including the full over-allotment from the underwriter. But as of Thursday, shares still trade well below the IPO price. Investors are watching revenue growth, losses, cash burn, and the timeline for the listing.
